Reports Q1 revenue $10.091M vs $1.292M last year. “We continue to engage with the FDA in the regulatory review process for obecabtagene autoleucel in adult ALL as we head towards the PDUFA target action date of November 16, 2024, and are driving commercial readiness activities across the Company,” said Dr. Christian Itin, Chief Executive Officer of Autolus. “We’re also delighted that our abstracts from the pivotal FELIX Phase 2 trial have been accepted for oral presentations at ASCO and EHA this year and we look forward to sharing further long-term data and additional subset analyses.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
- Autolus files to delay quarterly report, cancels earnings call
- Autolus Therapeutics Announces Q1 2024 Financial Update
- Autolus Therapeutics announces delay to Q1 earnings release, conference call
- AUTL Earnings this Week: How Will it Perform?